Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2

References

• Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat Rev Mol Cell Biol 2009;10:218–227.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Belloc F, Lagarde V, . MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368–2373.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Shiozawa K, Hassel BA, . Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 2006;108:678–684.
   PubMed Web of Science ®Google Scholar
• Widmer N, Colombo S, Buclin T, . Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003;102:1142.
   PubMed Web of Science ®Google Scholar
• Brendel C, Scharenberg C, Dohse M, . Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007;21:1267–1275.
   PubMed Web of Science ®Google Scholar
• Burger H, van Tol H, Boersma AW, . Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104:2940–2942.
   PubMed Web of Science ®Google Scholar
• Dai H, Marbach P, Lemaire M, . Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003;304:1085–1092.
   PubMed Web of Science ®Google Scholar
• Hegedus T, Orfi L, Seprodi A, . Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 2002;1587:318–325.
   PubMed Web of Science ®Google Scholar
• Dohse M, Scharenberg C, Shukla S, . Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010;38:1371–1380.
   PubMed Web of Science ®Google Scholar
• Davies A, Jordanides NE, Giannoudis A, . Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009;23:1999–2006.
   PubMed Web of Science ®Google Scholar
• Hegedus C, Ozvegy-Laczka C, Apati A, . Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 2009;158:1153–1164.
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Germain GS, Harwood FC, . Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004;64: 2333–2337.
   PubMed Web of Science ®Google Scholar
• Jordanides NE, Jorgensen HG, Holyoake TL, . Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006;108:1370–1373.
   PubMed Web of Science ®Google Scholar
• Liu W, Baer MR, Bowman MJ, . The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res 2007;13:2463–2470.
   PubMed Web of Science ®Google Scholar
• Tiwari AK, Sodani K, Wang SR, . Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 2009;78:153–161.
   PubMed Web of Science ®Google Scholar
• Szakacs G, Varadi A, Ozvegy-Laczka C, . The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 2008;13:379–393.
   PubMed Web of Science ®Google Scholar
• Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002;99:507–512.
   PubMed Web of Science ®Google Scholar
• Zhou S, Schuetz JD, Bunting KD, . The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7: 1028–1034.
   PubMed Web of Science ®Google Scholar
• Blume H, Donath F, Warnke A, . Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006;29: 769–784.
   PubMed Web of Science ®Google Scholar
• Breedveld P, Zelcer N, Pluim D, . Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004;64:5804–5811.
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus C, Murdter T, Godel A, . P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol 2001;363: 337–343.
   PubMed Web of Science ®Google Scholar
• Shi Z, Tiwari AK, Shukla S, . Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 2011;71:3029–3041.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Doki K, Homma M, . Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2009;67:44–49.
   PubMed Web of Science ®Google Scholar
• White D, Saunders V, Lyons AB, . In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005;106:2520–2526.
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P, . OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697–704.
   PubMed Web of Science ®Google Scholar
• Ozvegy C, Litman T, Szakacs G, . Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 2001;285:111–117.
   PubMed Web of Science ®Google Scholar
• Raaijmakers MH, de Grouw EP, van der Reijden BA, . ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia. Clin Cancer Res 2006;12: 3452–3458.
   PubMed Web of Science ®Google Scholar
• Crossman LC, Druker BJ, Deininger MW, . hOCT 1 and resistance to imatinib. Blood 2005;106:1133–1134; author reply 1134.
   PubMed Web of Science ®Google Scholar
• Thomas J, Wang L, Clark RE, . Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104:3739–3745.
   PubMed Web of Science ®Google Scholar
• Tanaka C, Yin OQ, Sethuraman V, . Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 2010;87:197–203.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Walters DK, Stoffregen EP, . In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500–4505.
   PubMed Web of Science ®Google Scholar
• Hughes T, Saglio G, Branford S, . Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204–4210.
   PubMed Web of Science ®Google Scholar
• Burger H, van Tol H, Brok M, . Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005;4:747–752.
   PubMed Web of Science ®Google Scholar
• Hirayama C, Watanabe H, Nakashima R, . Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharm Res 2008;25:827–835.
   PubMed Web of Science ®Google Scholar
• Illmer T, Schaich M, Platzbecker U, . P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004;18:401–408.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Deininger MW, Schultheis B, . Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070–1079.
   PubMed Web of Science ®Google Scholar
• Breedveld P, Pluim D, Cipriani G, . The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005;65:2577–2582.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Hayette S, Lagarde V, . Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008;68:9809–9816.
   PubMed Web of Science ®Google Scholar
• Dohse M, Scharenberg C, Shukla S, . Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010;38:1371–1380.
   PubMed Web of Science ®Google Scholar
• Ozvegy-Laczka C, Hegedus T, Varady G, . High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004;65:1485–1495.
   PubMed Web of Science ®Google Scholar
• Hiwase DK, White D, Zrim S, . Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia 2010;24: 658–660.
   PubMed Web of Science ®Google Scholar
• Hazarika M, Jiang X, Liu Q, . Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008;14:5325–5331.
   PubMed Web of Science ®Google Scholar
• Kerns EH, Di L. Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization. Amsterdam: Academic Press; 2008.
   Google Scholar
• White D, Dang P, Venables A, . ABCB1 overexpression may predispose imatinib treated CML patients to the development of Abl kinase domain mutations, and may be an important contributor to acquired resistance. Blood 2006;108(Suppl. 1): Abstract 2144.
   Google Scholar
• Tang C, Schafranek L, Watkins DB, . Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leuk Lymphoma 2011;52:2139–2147.
   PubMed Web of Science ®Google Scholar